Company intelligence / Profile preview

Shenzhen Neptunus

Shenzhen, Guangdong, Chinastatnews.com ↗

Ownership: Private
Employees: ~30000
Development stage: Other

Overview

Shenzhen Neptunus and its affiliates have several small molecule drugs in early clinical development for oncology indications such as advanced solid tumors and prostate cancer; they also market approved products for asthma, cough, hemorrhoids, and other conditions in China. The company is active in both innovative pharmaceuticals and traditional Chinese medicines with ongoing R&D efforts including international clinical trials.

Therapeutic areas: CardiovascularGastroenterologyPulmonologyOncology
Modalities: Small moleculeTraditional Chinese medicineBiologic
Industry: Pharma

Partnerships

MicroPortGSK

Beyond the preview

Go deeper on Shenzhen Neptunus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Neptunus.

Explore the full profile